<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Korean J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">KJO</journal-id>
      <journal-title-group>
        <journal-title>Korean Journal of Ophthalmology : KJO</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8942</issn>
      <publisher>
        <publisher-name>The Korean Ophthalmological Society</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17804928</article-id>
      <article-id pub-id-type="pmc">2629677</article-id>
      <article-id pub-id-type="doi">10.3341/kjo.2007.21.3.185</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Retinal Detachment with Macular Hole Following Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chung</surname>
            <given-names>Eun Jee</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Koh</surname>
            <given-names>Hyoung Jun</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <aff>The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.</aff>
      </contrib-group>
      <author-notes>
        <corresp>
Reprint requests to Hyoung Jun Koh, MD. Department of Ophthalmology, Yonsei University College of Medicine. 134 Sodaemungu Shinchondong, Seoul 120-752, Korea. Tel: 82-2-2228-3570, Fax: 82-2-312-0541, <email>hjkoh@yuns.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>9</month>
        <year>2007</year>
      </pub-date>
      <volume>21</volume>
      <issue>3</issue>
      <fpage>185</fpage>
      <lpage>187</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>4</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>7</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2007 The Korean Ophthalmological Society</copyright-statement>
        <copyright-year>2007</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Purpose</title>
          <p>To report a case of retinal detachment with a macular hole following photodynamic therapy (PDT) using verteporfin and intravtreal bevacizumab injection in the treatment of myopic choroidal neovasclarization (CNV).</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>A 58-year-old woman was diagnosed with myopic CNV and treated with a combination of PDT with verteporfin and intravitreal bevacizumab injection that same day. She received the second injection of intravitreal bevacizumab four weeks after the initial treatment.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The patient developed a sudden decline in vision one week after the second injection; and was subsequently diagnosed with retinal detachment associated with a macular hole. She underwent standard three-port pars plana vitrectomy with internal limiting membrane peeling, fluid-air exchange and silicone oil injection. The retina was still firmly attached at the patient's final follow-up visit.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>PDT and intravitreal bevacizumab injection used for the treatment of myopic CNV can be associated with retinal detachment with a macular hole. Patients need to be informed about this potential complication, and a higher index of suspicion may be warranted in patients who report sudden vision loss after the treatment.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Intravitreal bevacizumab injection</kwd>
        <kwd>Macular hole detachment</kwd>
        <kwd>Photodynamic therapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Recently, intravitreal bevacizumab (Avastin) injection has gained popularity as a potential treatment for choroidal neovascularization (CNV) associated with age related macular degeneration and pathologic myopia. The injection is utilized, either as a sole treatment or combined with photodynamic therapy (PDT) using verteporfin.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref> Although there is no definitive information on longterm safety for either intravitreal bevacizumab or combined treatment, these therapies are considered safe and have no known serious ocular or systemic adverse events.<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref></p>
    <p>Herein, we present a patient with myopic CNV, who developed retinal detachment with a macular hole following combined PDT and intravitreal bevacizumab injection.</p>
    <sec sec-type="cases">
      <title>Case Report</title>
      <p>A 58-year-old woman was diagnosed with CNV secondary to pathologic myopia in her right eye (right eye = -17 D, left eye = -15 D) (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The best corrected visual acuity in the affected eye as measured with a Snellen chart was 20/200. After an informed discussion of available therapies, the patient received combined PDT and 1.25 mg intravitreal bevacizumab injection. Four weeks after the initial treatment, the patient received a second intravitreal bevacizumab injection. Both treatments were uneventful.</p>
      <p>A week after receiving the second injection, the patient presented with worsening vision in her right eye. Her visual acuity was counting fingers at 1 m. Examination revealed retinal detachment involving the posterior pole with a macular hole. Ocular coherence tomography (OCT) confirmed the presence of a macular hole (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p>
      <p>The patient underwent standard three-port pars plana vitrectomy with internal limiting membrane peeling, fluid-air exchange and silicone oil injection. During the operation, peripheral fundus examination was performed with scleral indentation, and no additional peripheral hole was observed. On follow-up one week later, the macula had flattened and visual acuity was 20/400.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>The development of retinal detachment with a macular hole may occur as a spontaneous process in highly myopic eyes.<xref ref-type="bibr" rid="B4">4</xref> However, the retinal detachment with a macular hole in our patient occurred shortly after PDT and repeated injections of intravitreal bevacizumab. Therefore, the time course suggests the treatment had a potentially causal role.</p>
      <p>Several possible mechanisms may have induced the development of retinal detachment with a macular hole. The intravitreal injection may have induced vitreous incarceration at the needle insertion site, causing vitreoretinal traction leading to development of a macular hole and subsequent retinal detachment.<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref> We performed a combined treatment, and there has been a report of macular hole development several weeks after PDT treatment using verteporfin. Thus, PDT may have induced the development of the macular hole.<xref ref-type="bibr" rid="B8">8</xref> Lastly, bevacizumab itself may have caused the macular hole by modulating the permeability and activity of the CNV and inducing contraction of the vascular membrane, leading to exacerbation of tangential traction on the overlying retina.<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref> The short duration in the onset of retinal detachment with a macular hole after the second injection of intravitreal bevacizumab also suggests a possible causal role of the drug.</p>
      <p>In conclusion, PDT and intravitreal bevacizumab injection in the treatment of myopic CNV can be associated with retinal detachment with a macular hole. Patients need to be informed about this potential complication, and a higher index of suspicion may be warranted in patients who report sudden vision loss after the treatment.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laud</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Spaide</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Freud</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>960</fpage>
          <lpage>963</lpage>
          <pub-id pub-id-type="pmid">17031300</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhalla</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Blinder</surname>
              <given-names>KJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related maculra degeneration</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>988</fpage>
          <lpage>993</lpage>
          <pub-id pub-id-type="pmid">17151484</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fung</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Reichel</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide</article-title>
          <source>Br J Ophthalmol</source>
          <year>2006</year>
          <volume>90</volume>
          <fpage>1344</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="pmid">16854824</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kobayashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okinami</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Macular hole and myopic refraction</article-title>
          <source>Br J Ophthalmol</source>
          <year>2002</year>
          <volume>86</volume>
          <fpage>1269</fpage>
          <lpage>1273</lpage>
          <pub-id pub-id-type="pmid">12386087</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Mennel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kroll</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age related macular degeneration</article-title>
          <source>Br J Ophthalmol</source>
          <year>2006</year>
          <volume>90</volume>
          <fpage>1207</fpage>
          <lpage>1208</lpage>
          <pub-id pub-id-type="pmid">16929069</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bakri</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Kitzmann</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Retinal Pigment Epithelial Tear after Intravitreal Ranibizumab</article-title>
          <source>Am J Ophthlamol</source>
          <year>2007</year>
          <volume>143</volume>
          <fpage>505</fpage>
          <lpage>507</lpage>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konstantopoulos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>CPR</given-names>
            </name>
            <name>
              <surname>Newsom</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Luff</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Ocular morbidity associated with intravitreal triamcinolone acetonide</article-title>
          <source>Eye</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>317</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">16710433</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mansour</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Husseini</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Schakal</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Macular hole following photodynamic therapy</article-title>
          <source>Ophthalmic Surg Lasers</source>
          <year>2002</year>
          <volume>33</volume>
          <fpage>511</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="pmid">12449231</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mailhos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ju</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization</article-title>
          <source>Am J Pathol</source>
          <year>2006</year>
          <volume>168</volume>
          <fpage>2036</fpage>
          <lpage>2053</lpage>
          <pub-id pub-id-type="pmid">16723717</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Husain</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey</article-title>
          <source>Arch Ophthalmol</source>
          <year>2005</year>
          <volume>123</volume>
          <fpage>509</fpage>
          <lpage>516</lpage>
          <pub-id pub-id-type="pmid">15824225</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avery</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Pieramici</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Rabena</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration</article-title>
          <source>Ophthalmology</source>
          <year>2006</year>
          <volume>113</volume>
          <fpage>363</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="pmid">16458968</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>(A) Fundus photography of the right eye before treatment demonstrates a juxtafoveal grayish subretinal membrane with subretinal fluid and hemorrhage. (B) Late phase of the fluorescein angiography shows diffuse leakage from a juxtafoveal choroidal neovascularization.</p>
      </caption>
      <graphic xlink:href="kjo-21-185-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>(A) Fundus photography 5 weeks after initial combined treatment of PDT and intravitreal bevacizumab, and 1 week after the second intravitreal bevacizumab injection; demonstrating serous retinal detachment of the posterior pole with a macular hole. (B) OCT confirms the presence of a macular hole.</p>
      </caption>
      <graphic xlink:href="kjo-21-185-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
